Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
Stock Summary
Top Correlated Resources
RCEL
Top 10 Correlated ETFs
RCEL
Top 10 Correlated Stocks
RCEL
In the News
AVITA Medical® to Present at the Piper Sandler 34th Annual Healthcare Conference
VALENCIA, Calif., and MELBOURNE, Australia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today that its management team will present at the Piper Sandler 34th Annual Healthcare Conference in New York on Wednesday, November 30, 2022, at 4:30 p.m. Eastern Time.
AVITA Medical, Inc. (RCEL) Q3 2022 Earnings Call Transcript
AVITA Medical, Inc. (NASDAQ:RCEL ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Caroline Corner - Managing Director, Investor Relations Jim Corbett - Chief Executive Officer Michael Holder - Chief Financial Officer Conference Call Participants Charlie Montang - Lake Street Capital Matthew O'Brien - Piper Sandler Ryan Zimmerman - BTIG Joshua Jennings - Cowen Madeleine Williams - Wilsons Operator Good day and thank you for standing by and welcome to AVITA Medical Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.
AVITA Medical to Announce Third Quarter 2022 Financial Results
VALENCIA, Calif. and MELBOURNE, Australia, Oct. 20, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today that it will report its third quarter 2022 financial results after the close of the U.S. financial markets on Thursday, November 10, 2022. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, November 11, 2022, at 8:30 a.m. Australian Eastern Daylight Time) to discuss its financial results and recent highlights.
AVITA Medical, Inc. (RCEL) CEO Dr. Mike Perry on Q2 2022 Results - Earnings Call Transcript
AVITA Medical, Inc. (NASDAQ:RCEL ) Q2 2022 Results Conference Call August 11, 2022 5:00 PM ET Company Participants Caroline Corner - Managing Director, Investor Relations Dr. Mike Perry - Chief Executive Officer Michael Holder - Chief Financial Officer Conference Call Participants Josh Jennings - Cowen Ryan Zimmerman - BTIG Operator Hello. Thank you for standing by and welcome to the AVITA Medical Inc. Second Quarter 2022 Earnings Conference Call.
AVITA Medical to Announce Second Quarter 2022 Financial Results
VALENCIA, Calif., and MELBOURNE, Australia, July 25, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that it will release its second quarter 2022 financial results on Thursday, August 11, 2022. In conjunction with such release, the Company plans to host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time (Friday, August 12, 2022 at 7:00 a.m. Australian Eastern Standard Time) to discuss its financial results and recent highlights.
AVITA Medical, Inc. (RCEL) CEO Mike Perry on Q1 2022 Results - Earnings Call Transcript
AVITA Medical, Inc. (NASDAQ:RCEL ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Caroline Corner - Managing Director, Investor Relations Mike Perry - Chief Executive Officer Michael Holder - Chief Financial Officer Conference Call Participants Josh Jennings - Cowen Matthew O'Brien - Piper Sandler Ryan Zimmerman - BTIG Lyanne Harrison - Bank of America John Hester - Bell Potter Operator Good day and thank you for standing by. Welcome to the AVITA Medical Inc. First Quarter 2022 Conference Call.
AVITA Medical to Announce First Quarter 2022 Financial Results
VALENCIA, Calif. and MELBOURNE, Australia, April 28, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that it will release its first quarter 2022 financial results on Thursday, May 12, 2022. In conjunction with such release, the Company plans to host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time (Friday, May 13, 2022 at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent highlights.
AVITA Medical Inks Supply Pact With Premier For RECELL System
AVITA Medical Inc (NASDAQ: RCEL) has been awarded a group purchasing agreement with Premier Inc (NASDAQ: PINC) The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the RECELL System for.
AVITA Medical Inc. (RCEL) CEO Mike Perry on Q4 2021 Results - Earnings Call Transcript
AVITA Medical Inc. (RCEL) CEO Mike Perry on Q4 2021 Results - Earnings Call Transcript
AVITA Medical to Present at the Cowen 42nd Annual Health Care Conference
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that Dr. Mike Perry, CEO, will present at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 12:50 p.m. Eastern Standard Time (Wednesday, March 9, 2022 at 4:50 a.m. Australian Eastern Daylight Time).
Financial details
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-06-30
| Metric | History | 2017-06-30 | 2018-06-30 | 2019-06-30 | 2020-06-30 | 2021-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.12 | 0.09 | 0.43 | 0.7 | 1.29 | |
| Net income per share | -1.16 | -1.3 | -1.94 | -2.07 | -1.17 | |
| Operating cash flow per share | -1.12 | -1.28 | -1.52 | -1.12 | -1.14 | |
| Free cash flow per share | -0.9 | -1.32 | -1.62 | -1.16 | -1.19 | |
| Cash per share | 0.38 | 1.16 | 1.6 | 3.63 | 4.88 | |
| Book value per share | 0.51 | 1.49 | 1.65 | 3.57 | 5.1 | |
| Tangible book value per share | 0.51 | 1.49 | 1.63 | 3.55 | 5.08 | |
| Share holders equity per share | 0.51 | 1.49 | 1.65 | 3.57 | 5.1 | |
| Interest debt per share | 0 | 0.01 | 0.01 | 0 | 0.04 | |
| Market cap | 50.89M | 58.07M | 375.56M | 431.99M | 420.16M | |
| Enterprise value | 47.98M | 47.28M | 355.3M | 358.36M | 310.29M | |
| P/E ratio | -5.75 | -4.79 | -15.25 | -10.28 | -15.81 | |
| Price to sales ratio | 56.1 | 65.94 | 69.6 | 30.29 | 14.37 | |
| POCF ratio | -5.95 | -4.83 | -19.51 | -18.99 | -16.22 | |
| PFCF ratio | -7.37 | -4.69 | -18.31 | -18.31 | -15.52 | |
| P/B Ratio | 12.93 | 4.16 | 18 | 5.97 | 3.63 | |
| PTB ratio | 12.93 | 4.16 | 18 | 5.97 | 3.63 | |
| EV to sales | 52.89 | 53.68 | 65.84 | 25.12 | 10.61 | |
| Enterprise value over EBITDA | -5.05 | -3.63 | -14.53 | -8.63 | -12.02 | |
| EV to operating cash flow | -5.61 | -3.93 | -18.46 | -15.75 | -11.98 | |
| EV to free cash flow | -6.95 | -3.81 | -17.33 | -15.19 | -11.46 | |
| Earnings yield | -0.17 | -0.21 | -0.07 | -0.1 | -0.06 | |
| Free cash flow yield | -0.14 | -0.21 | -0.05 | -0.05 | -0.06 | |
| Debt to equity | 0 | 0.01 | 0 | 0 | 0.01 | |
| Debt to assets | 0.33 | 0.17 | 0.19 | 0.12 | 0.08 | |
| Net debt to EBITDA | 0.31 | 0.83 | 0.83 | 1.77 | 4.26 | |
| Current ratio | 2.86 | 5.74 | 5.5 | 10.17 | 16.42 | |
| Interest coverage | -1.53K | -675.05 | -946.78 | -1.29K | -1.21K | |
| Income quality | 0.97 | 0.99 | 0.78 | 0.54 | 0.97 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 10.24 | 6 | 2.35 | 2.43 | 0.77 | |
| Research and developement to revenue | 3.97 | 10.52 | 1.86 | 0.59 | 0.51 | |
| Intangibles to total assets | 0 | 0 | 0.01 | 0 | 0 | |
| Capex to operating cash flow | 0.04 | 0.03 | 0.07 | 0.04 | 0.05 | |
| Capex to revenue | -0.37 | -0.42 | -0.23 | -0.06 | -0.04 | |
| Capex to depreciation | -2.38 | -3.47 | -4.75 | -1.82 | -1.64 | |
| Stock based compensation to revenue | 0 | 0 | 0.36 | 1.16 | 0.19 | |
| Graham number | 3.66 | 6.59 | 8.49 | 12.9 | 11.6 | |
| ROIC | -3.81 | -0.94 | -1.17 | -0.57 | -0.22 | |
| Return on tangible assets | -1.5 | -0.72 | -0.97 | -0.51 | -0.21 | |
| Graham Net | 0.33 | 1.21 | 1.37 | 3.25 | 4.75 | |
| Working capital | 3.64M | 13.51M | 19.82M | 70.68M | 113.94M | |
| Tangible asset value | 0 | 0 | 20.64M | 72.04M | 115.18M | |
| Net current asset value | 3.64M | 13.41M | 19.35M | 68.33M | 111.48M | |
| Invested capital | 0 | 0.01 | 0 | 0 | 0.01 | |
| Average receivables | 2.01M | 3.21M | 2.26M | 2.43M | 5.16M | |
| Average payables | 2.55M | 2.27M | 2.4M | 4.33M | 3.73M | |
| Average inventory | 961.13K | 987.03K | 932.9K | 1.13M | 1.39M | |
| Days sales outstanding | 640.12 | 1.66K | 141.17 | 62.24 | 98.43 | |
| Days payables outstanding | 714.67 | 193.98 | 146 | 531.97 | 191.43 | |
| Days of inventory on hand | 748.93 | 824.55 | 227.4 | 138.12 | 101.05 | |
| Receivables turnover | 0.57 | 0.22 | 2.59 | 5.86 | 3.71 | |
| Payables turnover | 0.51 | 1.88 | 2.5 | 0.69 | 1.91 | |
| Inventory turnover | 0.49 | 0.44 | 1.61 | 2.64 | 3.61 | |
| ROE | -2.25 | -0.87 | -1.18 | -0.58 | -0.23 | |
| Capex per share | -0.04 | -0.04 | -0.1 | -0.04 | -0.05 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-06-30 | 2021-09-30 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.41 | 0.28 | 0.3 | 0.33 | 0.36 | |
| Net income per share | -0.19 | -0.24 | -0.38 | -0.25 | -0.22 | |
| Operating cash flow per share | -0.16 | -0.02 | -0.38 | -0.14 | -0.63 | |
| Free cash flow per share | -0.17 | -0.03 | -0.38 | -0.15 | -0.64 | |
| Cash per share | 4.45 | 3.62 | 3.34 | 3.38 | 3.37 | |
| Book value per share | 4.65 | 4.48 | 3.92 | 3.71 | 3.52 | |
| Tangible book value per share | 4.63 | 4.46 | 3.91 | 3.69 | 3.51 | |
| Share holders equity per share | 4.65 | 4.48 | 3.92 | 3.71 | 3.52 | |
| Interest debt per share | 0.04 | 0.04 | 0.03 | 0.02 | 0.02 | |
| Market cap | 510.14M | 441.32M | 211.47M | 118.61M | 131.79M | |
| Enterprise value | 400.27M | 381.95M | 188.67M | 84.41M | 108.58M | |
| P/E ratio | -27.03 | -18.55 | -5.59 | -4.74 | -5.9 | |
| Price to sales ratio | 49.51 | 62.87 | 28.05 | 14.23 | 14.49 | |
| POCF ratio | -129.12 | -771.55 | -22.57 | -33.82 | -8.42 | |
| PFCF ratio | -122.87 | -668.67 | -22.39 | -31.71 | -8.22 | |
| P/B Ratio | 4.41 | 3.96 | 2.16 | 1.28 | 1.5 | |
| PTB ratio | 4.41 | 3.96 | 2.16 | 1.28 | 1.5 | |
| EV to sales | 38.85 | 54.41 | 25.03 | 10.13 | 11.94 | |
| Enterprise value over EBITDA | -88.42 | -66.32 | -20.3 | -13.8 | -21.08 | |
| EV to operating cash flow | -101.31 | -667.74 | -20.14 | -24.07 | -6.94 | |
| EV to free cash flow | -96.41 | -578.71 | -19.97 | -22.56 | -6.77 | |
| Earnings yield | -0.01 | -0.01 | -0.04 | -0.05 | -0.04 | |
| Free cash flow yield | -0.01 | 0 | -0.04 | -0.03 | -0.12 | |
| Debt to equity | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
| Debt to assets | 0.08 | 0.08 | 0.08 | 0.1 | 0.12 | |
| Net debt to EBITDA | 24.27 | 10.31 | 2.45 | 5.59 | 4.5 | |
| Current ratio | 16.42 | 13.77 | 13.96 | 11.64 | 9.64 | |
| Interest coverage | -522.67 | -661 | 0 | -1.59K | -1.11K | |
| Income quality | 0.84 | 0.1 | 0.99 | 0.56 | 2.8 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.51 | 0.76 | 1 | 0.66 | 0.55 | |
| Research and developement to revenue | 0.39 | 0.48 | 0.48 | 0.37 | 0.42 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.05 | 0.15 | 0.01 | 0.07 | 0.02 | |
| Capex to revenue | -0.02 | -0.01 | -0.01 | -0.03 | -0.04 | |
| Capex to depreciation | -1.15 | -0.51 | -0.47 | -1.71 | -0.9 | |
| Stock based compensation to revenue | 0.14 | 0.26 | 0.39 | 0.17 | 0.64 | |
| Graham number | 4.46 | 4.9 | 5.79 | 4.57 | 4.21 | |
| ROIC | -0.04 | -0.05 | -0.09 | -0.07 | -0.07 | |
| Return on tangible assets | -0.04 | -0.05 | -0.09 | -0.06 | -0.06 | |
| Graham Net | 4.33 | 3.38 | 3.16 | 3.15 | 3.04 | |
| Working capital | 113.94M | 90.08M | 84.19M | 83.92M | 82.21M | |
| Tangible asset value | 115.18M | 111.02M | 97.4M | 92.13M | 87.81M | |
| Net current asset value | 111.48M | 87.45M | 82.01M | 81.7M | 80.05M | |
| Invested capital | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
| Average receivables | 6.14M | 4.07M | 4.35M | 4.39M | 3.97M | |
| Average payables | 2.81M | 2.47M | 2.45M | 2.5M | 0 | |
| Average inventory | 1.83M | 1.96M | 1.91M | 2.02M | 1.99M | |
| Days sales outstanding | 68.85 | 48.19 | 51.49 | 47.37 | 35.17 | |
| Days payables outstanding | 136.78 | 201.76 | 121.33 | 162.01 | 0 | |
| Days of inventory on hand | 72.2 | 156.51 | 91.27 | 131.3 | 115.29 | |
| Receivables turnover | 1.31 | 1.87 | 1.75 | 1.9 | 2.56 | |
| Payables turnover | 0.66 | 0.45 | 0.74 | 0.56 | 0 | |
| Inventory turnover | 1.25 | 0.58 | 0.99 | 0.69 | 0.78 | |
| ROE | -0.04 | -0.05 | -0.1 | -0.07 | -0.06 | |
| Capex per share | -0.01 | 0 | 0 | -0.01 | -0.02 |
Frequently Asked Questions
What is AVITA Medical, Inc. stock symbol ?
AVITA Medical, Inc. is a US stock , located in Valencia california of California and trading under the symbol RCEL
What is AVITA Medical, Inc. stock quote today ?
AVITA Medical, Inc. stock price is $6.7 today.
Is AVITA Medical, Inc. stock public?
Yes, AVITA Medical, Inc. is a publicly traded company.
Company Profile
- Volume Average 83.85K
- Market Capitalization 167.46M
- Employee 116
- CEO Dr. Michael S. Perry D.V.M., DVM, Ph.D., FACVPT
- Headquarters Valencia California,CALIFORNIA,US
- IPO Date 2012-03-18
-
Website
https://www.avitamedical.com 
AVITA Medical, Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's skin to use in the treatment of acute thermal burns in patients eighteen years and older. AVITA Medical, Inc. has a research agreement with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. was incorporated in 2000 and is based in Valencia, California.
